Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Bladder Cancer
Interventions
DRUG

Gemcitabine and Cisplatin (DD GC)

Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)

Trial Locations (8)

10010

New York University, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering West Harrison, Harrison

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

27514

University of North Carolina, Chapel Hill

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

Unknown

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow

All Listed Sponsors
collaborator

University of North Carolina, Chapel Hill

OTHER

collaborator

New York University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01589094 - Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter